Mecamylamine

A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

Also Known As:

Networked: 301 relevant articles (13 outcomes, 24 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shytle, R D: 9 articles (07/2002 - 01/2000)
2.	Sanberg, P R: 9 articles (07/2002 - 01/2000)
3.	George, Tony P: 7 articles (12/2009 - 04/2005)
4.	Vessicchio, Jennifer C: 5 articles (03/2007 - 04/2005)
5.	Sacco, Kristi A: 5 articles (03/2007 - 04/2005)
6.	Silver, A A: 5 articles (07/2002 - 01/2000)
7.	Termine, Angelo: 4 articles (10/2006 - 04/2005)
8.	Newman, M B: 4 articles (01/2002 - 04/2001)
9.	Cooke, John P: 3 articles (05/2010 - 09/2003)
10.	Zarrindast, Mohammad-Reza: 3 articles (07/2008 - 05/2002)

Related Diseases

1.	Tremor (Tremors) 05/01/1995 - "Intraperitoneal (20 mg/kg) or i.c.v. (60 micrograms/mouse) injection of mecamylamine further strengthened the tremor. " 03/08/1958 - "Psychosis and tremor due to mecamylamine." 08/01/2001 - "After chronic nicotine administration for 7 days, the nicotinic antagonist mecamylamine (1.0 mg/kg, s.c.) precipitated withdrawal with the appearance of somatic signs (teeth chattering and shakes/tremors) and a significant increase in extracellular ACh to 125% of baseline, while extracellular DA decreased to 65%. " 05/01/1997 - "Mecamylamine (0.5 mg/kg, i.p), administered before the nicotine injection on each day, abolished the tail-tremor. " 06/01/1975 - "Both tremor and antidiuresis correlate fairly well with brain nicotine levels whereas mecamylamine-nicotine antagonism is less clearly reflected in brain nicotine levels."
2.	Alcoholism (Alcohol Abuse) 02/01/2012 - "This ability of mecamylamine might be a potential advantage in the treatment of alcoholism." 10/09/1998 - "Thus, mecamylamine or other antagonists specifically aimed at ventral tegmental nicotinic acetylcholine receptors could represent a new pharmacological treatment principle against alcohol abuse, the efficacy of which should be explored in high-scale alcohol consumers or alcoholics." 01/01/2009 - "These results provide further support that mecamylamine is effective in reducing alcohol consumption and preference, and nicotinic-receptor-based drugs could further be explored as potential treatments for alcoholism."
3.	Tobacco Use Disorder (Nicotine Dependence) 02/01/2007 - "Mecamylamine produced a significant increase in overt signs of withdrawal in the 23-hour access animals comparable to that observed in previous studies of nicotine dependence. " 02/01/2008 - "As bPiDDB has properties different from the prototypical nAChR antagonist mecamylamine, further development may lead to novel nAChR antagonists for the treatment of tobacco dependence." 02/01/2007 - "Nicotine dependence was assessed by examining physical signs of withdrawal following an injection of the nicotinic antagonist mecamylamine (1.5 mg/kg, i.p.). " 03/01/1984 - "Mecamylamine (MCL) has been shown to extinguish nicotine dependence in rats and monkeys. " 03/01/1984 - "Clinical evaluation of mecamylamine for withdrawal from nicotine dependence."
4.	Tourette Syndrome (Tourette's Syndrome) 09/01/2001 - "The safety and efficacy of mecamylamine as a monotherapy in children and adolescents with Tourette's disorder (TD) was investigated in an 8-week multicenter, double-blind, placebo-controlled study. " 09/01/2001 - "Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder." 04/01/2001 - "4. These findings may have important therapeutic implications since clinical observations have shown that low doses of mecamylamine reduce tension and anxiety in patients with Tourette syndrome." 01/01/2000 - "Mecamylamine in Tourette's syndrome: a two-year retrospective case study." 08/29/1998 - "Treatment of Tourette's syndrome with mecamylamine."
5.	Poisoning 06/18/1986 - "Since: spontaneous activity of Renshaw cells is related to the respiratory drive; persists after C7 spinal transection and after mecamylamine poisoning of the axonal recurrent pathway; and might appear before sustained phrenic activity, the assumption of a central respiratory drive impinging on the Renshaw cells has to be retained." 01/01/1988 - "Many lines of evidence support the importance of direct interactions with various sites on the AChR: 1) morphological and toxicological studies with (+) physostigmine showed that anti-ChE activity is not essential to protect animals against toxicity by irreversible ChE inhibitors; 2) (-)physostigmine is far more effective against OP poisoning; 3) open channel blockers such as mecamylamine with no significant anti-ChE activity enhance the protective action of (-)physostigmine; 4) neostigmine, pyridostigmine, (-)physostigmine and (+)physostigmine showed qualitatively and quantitatively distinct toxicity and damage to endplate morphology and function. " 01/01/1988 - "2. In prophylaxis and during the very early phase of OP poisoning, carbamates, especially (-)physostigmine combined with mecamylamine and atropine, could protect almost 100% of the animals exposed to multiple lethal doses of OPs. " 01/01/1986 - "Prophylactic Action of Hexamethonium, Trimethaphan, and Mecamylamine against Diisopropyl Fluorophosphate Poisoning in Mice. " 01/01/1986 - "Prophylactic action of hexamethonium, trimethaphan, and mecamylamine against diisopropyl fluorophosphate poisoning in mice."

Related Drugs and Biologics

1.	Nicotine
2.	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
3.	Physostigmine
4.	Neostigmine (Neostigmine Bromide)
5.	varenicline (Chantix)
6.	Pyridostigmine Bromide (Pyridostigmine)
7.	Naloxone (Narcan)
8.	Morphine (MS Contin)
9.	Acetylcholine (Acetylcholine Chloride)
10.	Haloperidol (Haldol)

Related Therapies and Procedures

1.	Ligation
2.	Self Administration (Administration, Self)
3.	Injections
4.	Drug Therapy (Chemotherapy)
5.	Analgesia